SBOT - Stellar Biotechnologies, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.11
-0.13 (-5.80%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.24
Open2.23
Bid1.05 x 1000
Ask2.39 x 800
Day's Range2.04 - 2.28
52 Week Range2.04 - 10.85
Volume238,171
Avg. Volume65,567
Market Cap6.744M
Beta-0.38
PE Ratio (TTM)N/A
EPS (TTM)-0.48
Earnings DateFeb 8, 2018 - Feb 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Trade prices are not sourced from all markets
  • PR Newswire6 days ago

    Stellar Biotechnologies Announces Closing of $5.5 Million Public Offering

    LOS ANGELES, May 15, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, lupus and cancers, among other diseases, announced today the completion of its previously announced public offering of 2,075,472 units (the "Units"), with each Unit consisting of (i) one common share, no par value per share (the "Common Shares") or Common Share equivalent, and (ii) one warrant to purchase one Common Share for aggregate gross proceeds of $5.5 million. The offering was priced at $2.65 per Common Share (or Common Share equivalent), with each Common Share (or Common Share equivalent) sold with one five-year warrant to purchase one Common Share, at an exercise price of $2.65.

  • Zacks Small Cap Research11 days ago

    SBOT: Q2 2018 Financial Results/Update: Neovacs reiterates Ph2 Lupus data expected in June

    Revenue, which was just about dead-on with our estimate, remains at relatively very low levels, reflecting the conclusion of several mid-stage clinical trials that SBOT supported via supply of KLH. Additionally, an eventual supply agreement for a commercialized product (potentially such as Neovacs’ IFNa-Kinoid candidate) would likely significantly steepen the revenue curve. As we have noted in the recent past, while revenue has largely been negligible, we had anticipated as much given that current demand is dependent on timing of activity of the company’s clinical trial customers.

  • Benzinga11 days ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Trade Desk Inc (NASDAQ: TTD ) stock soared nearly ...

  • PR Newswire11 days ago

    Stellar Biotechnologies Announces Pricing of $5.5 Million Public Offering

    LOS ANGELES, May 11, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, lupus and cancers, among other diseases, today announced the pricing of a public offering of an aggregate of 2,075,472 units (the "Units"), with each Unit consisting of (i) one common share, no par value per share (the "Common Shares") or Common Share equivalent, and (ii) one warrant to purchase one Common Share (the "Warrants"). H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The Common Shares or Common Share equivalents and the accompanying Warrants can only be purchased together in this offering but will be issued separately.

  • CNW Group11 days ago

    Stellar Biotechnologies Announces Pricing of $5.5 Million Public Offering

    LOS ANGELES , May 11, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, lupus and cancers, among other diseases, today announced the pricing of a public offering of an aggregate of 2,075,472 units (the "Units"), with each Unit consisting of (i) one common share, no par value per share (the "Common Shares") or Common Share equivalent, and (ii) one warrant to purchase one Common Share (the "Warrants"). H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The Common Shares or Common Share equivalents and the accompanying Warrants can only be purchased together in this offering but will be issued separately.

  • PR Newswire15 days ago

    Stellar Biotechnologies Reports Second Quarter Financial Results

    LOS ANGELES , May 7, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, ...

  • PR Newswire2 months ago

    Stellar Biotech Begins Scale-Up and Expansion Project at Port Facility

    LOS ANGELES, March 29, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, lupus and cancers, among other diseases, initiated the second phase of an expansion project at the Port of Hueneme, north of Los Angeles, California. The construction project will allow the company to expand production of a medical-grade protein, called KLH, which Stellar produces in aquaculture from a marine mollusk. The plan includes 10,000 square feet of renovated Pacific ocean-front space for aquaculture production and related activities as well as new protective structures and aesthetic improvements.

  • PR Newswire3 months ago

    Stellar Biotechnologies Appoints Bioprocess Expert to Lead Manufacturing

    LOS ANGELES, Feb. 27, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, diabetes, lupus and cancers, among other diseases, today announced that Michael Kennedy has joined the company to lead the company's manufacturing activities. Kennedy, who has extensive bioprocessing experience over the last 26 years related to advancing biopharmaceutical products from clinical to commercial manufacturing, will manage the company's optimization and scale-up activities, and oversee manufacturing and purification processes at Stellar's California manufacturing facility, which operates under current Good Manufacturing Practices (cGMP). "Michael is an excellent addition to our manufacturing team.

  • Zacks Small Cap Research3 months ago

    SBOT: Potential Key Milestone Upcoming As Neovacs Confirms Ph2 Lupus Data Expected June 2018

    Stellar (SBOT) reported financial results for their fiscal 2018 first quarter ending December 31, 2017.  Revenue continues at relatively very low levels, reflecting the conclusion of several mid-stage clinical trials that SBOT supported via supply of KLH.  But with development progression to (larger) later-stage studies, we continue to expect SBOT’s revenue to return to growth.  Additionally, an eventual supply agreement for a commercialized product (potentially such as Neovacs’ IFNa-Kinoid candidate) would likely significantly steepen the revenue curve.

  • PR Newswire3 months ago

    Stellar Biotechnologies Reports First Quarter 2018 Financial Results

    LOS ANGELES , Feb. 7, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, ...

  • PR Newswire4 months ago

    Stellar Biotechnologies Appoints Pharma Licensing Expert to Board of Directors

    LOS ANGELES, Jan. 25, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. (SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, diabetes, lupus and cancers, among other diseases, today announced the appointment of Deborah F. Aghib, Ph.D. to the company's Board of Directors. "Deborah will bring to the company significant international experience in developing technology licensing and business development strategies for life science companies as well as an in-depth understanding of the KLH business. "It is my pleasure to join Stellar's Board of Directors.

  • ACCESSWIRE5 months ago

    Wired News – Asterias Reports Enrollment and Dosing of Last Subject in SciStar Trial In Treatment of Severe Spinal Cord Injury

    Stock Monitor: Stellar Biotechnologies Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 21, 2017 / Active-Investors.com has just released a free report on Asterias Biotherapeutics, Inc. (NYSE: ...

  • Zacks Small Cap Research5 months ago

    SBOT: Important Clinical Program Related Milestones Upcoming

    Stellar (SBOT) reported financial results for their fiscal 2017 fourth quarter ending September 30th.  Revenue continues at relatively very low levels, reflecting the conclusion of several mid-stage clinical trials that SBOT supported via supply of KLH.  But with development progression to (larger) later-stage studies, we continue to expect SBOT’s revenue to return to growth.  Additionally, an eventual supply agreement for a commercialized product (potentially such as Neovacs’ IFNa-Kinoid candidate) would likely significantly steepen the revenue curve.

  • Stellar Biotechnologies, Inc. :SBOT-US: Earnings Analysis: 2017 By the Numbers : December 5, 2017
    Capital Cube6 months ago

    Stellar Biotechnologies, Inc. :SBOT-US: Earnings Analysis: 2017 By the Numbers : December 5, 2017

    Categories: Yahoo FinanceGet free summary analysis Stellar Biotechnologies, Inc. reports financial results for the year ended September 30, 2017. We analyze the earnings along side the following peers of Stellar Biotechnologies, Inc. – Omeros Corporation, Onconova Therapeutics Inc. and OncoMed Pharmaceuticals, Inc. (OMER-US, ONTX-US and OMED-US) that have also reported for this period. Highlights Gross margins narrowed ... Read more (Read more...)

  • PR Newswire6 months ago

    Stellar Biotechnologies Reports Fiscal Year 2017 Financial Results

    - Company prepares to support expanded market opportunities - Expenditures in line with management plans LOS ANGELES , Dec. 1, 2017 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading ...

  • Zacks Small Cap Research6 months ago

    SBOT: Neovacs' Ph IIb Lupus Study Could Read-Out 1H 2018

    • Neovacs IND approved, allowing for Phase IIa dermatomyositis study to expand to U.S. ➢ …in early March 2017 SBOT announced that they entered an exclusive multi-year agreement with Amaran Biotechnology whereby Stellar will supply KLH for Amaran’s partners (i.e.

  • PR Newswire6 months ago

    Stellar Biotechnologies to Present at the LD Micro Main Event Investor Conference

    LOS ANGELES, Nov. 29, 2017 /PRNewswire/ -- Stellar Biotechnologies, Inc. (SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer's, diabetes, lupus and cancers, among other diseases, today announced that Stellar President and CEO Frank Oakes will present at the 10th Annual LD Micro Main Event investor conference to be held December 5-7, 2017 in Los Angeles, California. The company will provide a review of its Stellar KLH business and recent corporate activities. Members of the investment community who are interested in meeting with Stellar should contact LD Micro Conference coordinators to arrange an appointment.

  • Should You Buy Stellar Biotechnologies Inc (SBOT) Now?
    Simply Wall St.7 months ago

    Should You Buy Stellar Biotechnologies Inc (SBOT) Now?

    Stellar Biotechnologies Inc (NASDAQ:SBOT), a biotechnology company based in United States, received a lot of attention from a substantial price movement on the NasdaqCM in the over the last fewRead More...

  • Zacks Small Cap Research9 months ago

    SBOT: Neovacs Ph 2 Lupus Study Completes Enrollment. Read-Out Q2 2018

    Stellar (SBOT) reported financial results for their fiscal 2017 third quarter ending June 30th.  Revenue was again meager and, while below our estimate, we continue to remind investors that we had and continue to expect relatively limited top-line numbers over the near-term, reflecting expectations that supply agreements with clinical trial customers account for the bulk of sales.  Although we do expect some revenue growth related to progression of customers’ clinical trials to later stages (for example, OBI recently moving into phase III), an eventual supply agreement for a commercialized product (potentially such as Neovacs’ IFNa-Kinoid candidate) would likely significantly steepen the revenue curve. Q3 revenue was $21k (vs. $341k estimate), with all coming from product sales.  While this is down 89% yoy (from $181k) and 68% sequentially (from $63k) and the lowest top-line number in 13 quarters, it is important to keep this in the context that there will be variability in demand based on snapshots of activity of the clinical trials and other development programs that Stellar supports.  As such, periods of relative weakness in revenue should not be interpreted as being representative of operational progress or future growth potential.

  • Stellar Biotechnologies, Inc. :SBOT-US: Earnings Analysis: Q3, 2017 By the Numbers : August 24, 2017
    Capital Cube9 months ago

    Stellar Biotechnologies, Inc. :SBOT-US: Earnings Analysis: Q3, 2017 By the Numbers : August 24, 2017

    Categories: Yahoo FinanceGet free summary analysis Stellar Biotechnologies, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Stellar Biotechnologies, Inc. – OncoMed Pharmaceuticals, Inc., Omeros Corporation and Onconova Therapeutics Inc. (OMED-US, OMER-US and ONTX-US) that have also reported for this period. Highlights Summary numbers: Revenues ... Read more (Read more...)

  • PR Newswire9 months ago

    Stellar Biotechnologies Reports Third Quarter 2017 Financial Results

    - Company prepares for collaborators' Phase 2 clinical results LOS ANGELES , Aug. 9, 2017 /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized ...

  • PR Newswire11 months ago

    Stellar Biotechnologies Expands Operations Team

    LOS ANGELES, June 7, 2017 /PRNewswire/ -- Stellar Biotechnologies, Inc. (SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer's, diabetes and lupus, among other diseases, today announced that the company has expanded its operations team, including key additions in manufacturing and aquaculture. The new managers and scientists are part of the company's plans to optimize its manufacturing process and increase throughput capacity. "These scientists and industry experts bring valuable experience in scaling up production, process validation and regulatory compliance, and we are confident that they will contribute greatly to our growth initiatives," said Gregory T. Baxter, PhD, Stellar Executive Vice President of Corporate Development.

  • Stellar Biotechnologies, Inc. :SBOT-US: Earnings Analysis: Q2, 2017 By the Numbers : June 2, 2017
    Capital Cubelast year

    Stellar Biotechnologies, Inc. :SBOT-US: Earnings Analysis: Q2, 2017 By the Numbers : June 2, 2017

    Categories: Yahoo FinanceGet free summary analysis Stellar Biotechnologies, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Stellar Biotechnologies, Inc. – OncoMed Pharmaceuticals, Inc., Omeros Corporation and Onconova Therapeutics Inc. (OMED-US, OMER-US and ONTX-US) that have also reported for this period. Highlights Summary numbers: Revenues ... Read more (Read more...)

  • PR Newswirelast year

    Stellar Biotechnologies to Present at Marcum Investor Conference

    LOS ANGELES, May 31, 2017 /PRNewswire/ -- Stellar Biotechnologies, Inc. (SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer's, diabetes and lupus, among other diseases, today announced that Stellar President and CEO Frank Oakes will present at the Marcum Microcap Conference to be held June 15-16, 2017 in New York City. The company will provide a review of its Stellar KLH business and recent corporate activities. Members of the investment community who are interested in meeting with Stellar should contact Marcum conference coordinators to arrange an appointment.